Get more information on Psoriatic Arthritis Treatment Market - Request Sample Report
Psoriatic Arthritis Treatment Market was valued at USD 11.08 billion in 2023 and is expected to reach USD 25.41 billion by 2032, growing at a CAGR of 9.70% from 2024-2032.
The psoriatic arthritis treatment market report presents unique insights by taking a deeper dive into critical data points, including the incidence and prevalence of psoriatic arthritis in 2023, with the regional variations and disease burden. It analyzes prescription trends across regions and, more specifically, focuses on drug utilization patterns and preferred therapies. The report also assesses healthcare spending by region, where discrepancies in expenditure and access to treatment are depicted. It also offers an in-depth review of drug development and approval trends, with emerging therapies and regulatory milestones. The report also looks into patient demographics and treatment adherence, with a focus on the impact of age, gender, and compliance on therapeutic outcomes.
Market dynamics
Drivers
The increasing global prevalence of psoriatic arthritis (PsA) is a significant driver for the treatment market.
The increasing global prevalence of psoriatic arthritis (PsA) is significantly driving the Psoriatic Arthritis Treatment Market. Approximately 125 million people worldwide live with psoriasis, and about 30% of these individuals develop PsA, which equates to over 37 million people globally. In the U.S., around 1.5 million individuals are affected by PsA. With the aging population and rising incidence of chronic conditions, the prevalence is expected to continue to grow. Advances in biologic treatments, such as Janssen’s TREMFYA and Otezla (apremilast), which was FDA-approved for PsA, offer more effective management options, propelling further market expansion. Additionally, the growing awareness of PsA among healthcare providers and patients, along with ongoing research and development of targeted therapies, is contributing to increased diagnosis rates and treatment adoption. The expanding pipeline of novel therapies further boosts treatment options, driving market growth.
The rising awareness about PsA and its impact on patient's quality of life is leading to better early diagnosis and more timely treatments.
Rising Knowledge about Psoriatic Arthritis (PsA) and its effect on patient quality of life Driving Psoriatic Arthritis Treatment MarketPsoriatic arthritis (PsA) is an autoimmune disease that negativrly effects joints with potential for deformaties. According to studies, timely diagnosis and treatment can prevent joint damage by up to 70%, making timely interventions critical. As such, organizations like the American College of Rheumatology (ACR) and and outreach initiatives from pharmaceutical companies, such as Novartis, have been more proactive in raising awareness and encouraging early detection. In addition, emerging treatments (the FDA recently approved intravenous Cosentyx [secukinumab] in 2023) will only further refine the already wide range of effective treatments and enhance overall patient outcomes. The increasing emphasis on personalized medicine and biologic therapies by moderate-to-severe PsA cases is also driving an increase in treatment penetration. Continued market growth is expected as awareness increases and patients are diagnosed earlier, leading to increased patient demand for advanced treatment options such as biologics and targeted therapies. Together, along with the support from healthcare professionals, patient advocacy groups, and regulatory approvals, will aid in boosting the overall market dynamics.
Restraint
One of the significant restraints in the Psoriatic Arthritis Treatment Market is the high cost of advanced biologic therapies and treatments.
The high cost of advanced biologic therapies is a significant restraint in the Psoriatic Arthritis Treatment Market as it is an income generator and this limits the access to treatment for a large number of patients. Medications such as Otezla (apremilast) and TREMFYA (guselkumab), while effective at managing plaque psoriasis symptoms, come with surprisingly high price tags, upwards of USD 10,000 to 40,000 yearly. Though they provide clinically meaningful improvements in patient outcomes, these therapies are not always fully reimbursed by the insurance in some markets, especially in low- to middle-income territories. Besides the expense that patients have to face, high costs burden health systems, worsening the issue. Due to the restricted access to these therapies, the effective management of PsA is not achievable in a larger population, which limits the overall potential of market expansion. Over time, attempts to expand insurance coverage, lower drug prices, and improve patient access to biologics could lessen this restraint, but in the near term it is a major market barrier.
Opportunities
Expansion in Emerging Markets in various regions, making space for the Psoriatic Arthritis Treatment Market
The psoriatic Arthritis Treatment Market holds huge growth opportunities in emerging markets, including Asia-Pacific, Latin America, and the Middle East & Africa. Improved health infrastructures are leading to enhancements of healthcare systems in these regions. Raised disease awareness is influenced by increased disposable incomes and the ever-growing prevalence of psoriatic arthritis in these geographies that push demand for advanced therapies. For example, efforts to push for early detection and biosimilar adoption are gradually making treatments available and affordable. According to the GaBI 2024 report mentioned that biosimilars in biologic treatments have entered India and Brazil. This is also a great challenge for pharmaceutical giants to expand into these untapped markets.
Challenges
Lack of awareness about the disease among patients and healthcare providers, which usually results in late diagnosis and treatment.
One of the major challenges in the Psoriatic Arthritis Treatment Market is the lack of awareness among the patients and the healthcare professionals leading to delayed diagnosis and treatment. Clinical studies suggest that up to 30% of psoriasis patients who have psoriatic arthritis fail to get diagnosed because those early signs like stiffness and mild swelling are often mistakenly linked with other issues or ignored altogether. As a result, this delay in identifying such disorders can cause irreversible joint damages, a higher economic burden (more healthcare costs), and a drastic loss of quality of life for patients. Furthermore, the diagnosis is also delayed which may render potential treatment options less effective (the sooner the treatment, the lesser the chances of the disease to progress.) This is a problem that can be tackled only with educational campaigns targeting both patients and health care professionals and with improved screening methods.
Market segmentation
By Drugs Class
The biologics segment dominated the psoriatic arthritis treatment market with 31.54% market share in 2023. These drugs offer efficacy that cannot be matched, focusing on the pathways of the underlying immune processes. Biologics, for instance, including TNF inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors, present meaningful clinical benefits for patients with psoriatic arthritis, including reductions in inflammation and prevention of damage to joints as well as amelioration of skin manifestations. Their use is backed by robust clinical evidence as well as regulatory approvals for first-line treatment in mild to severe instances. Furthermore, more patients have been gaining access to biologics due to the reimbursement policies of governments, as well as improvement in healthcare infrastructure across developed markets.
The DMARDs segment is expected to have the fastest growth rate during the forecast years with the help of cost-effectiveness and the capability to manage cases of mild to moderate psoriatic arthritis. The increasing utilization of both conventional and targeted synthetic DMARDs, such as methotrexate and JAK inhibitors, is primarily on account of greater awareness among both healthcare providers and patients about the importance of early disease management. The adoption rate of DMARDs is especially high in emerging economies, where biologics may not be as accessible due to cost barriers. Additionally, research into novel DMARD formulations with fewer side effects and improved efficacy is an ongoing process, which contributes to the robust growth trajectory of this segment.
By Route of Administration
The injectable segment dominated the psoriatic arthritis treatment market with a 42.13% market share in 2023. This is primarily because biological therapies, highly effective for the management of moderate-to-severe cases, are administered via this route. Injectable formulations ensure that the drugs directly enter the bloodstream, thereby causing rapid relief of symptoms and greater adherence in patients requiring long-term disease control. TNF inhibitors and IL-17 inhibitors are the leading biologics in injectable forms, further fueling the dominance of this segment. Besides, self-injection devices in the form of pre-filled syringes and auto-injectors improve patient convenience and thus widely adopted injectables in managing psoriatic arthritis.
The oral segment is expected to grow the fastest, with 11.42% CAGR during the forecast period, due to the increased popularity of drugs for small molecules, including JAK inhibitors and PDE4 inhibitors. Oral drugs are convenient options that don't require hospital visits or even administration by highly trained professionals. The trend is further being accelerated by growing interest in the approach of patient-centric treatment options and the availability of effective oral drugs, such as Otezla (apremilast). Moreover, this rapidly expanding segment is also expected to be fueled by the growing pipeline of oral therapeutics targeting novel pathways and the affordability of generic oral drugs in emerging markets.
By Distribution Channel
In 2023, The hospital pharmacies segment dominated the market with the highest market share. This is mainly because most of the advanced biologics and specialty drugs are dispensed centrally from these pharmacies. These are equipped with complex drugs that need to be stored in cold conditions and under strict protocols. Patients suffering from severe psoriatic arthritis prefer hospital pharmacies since treatments are generally received under the care of specialists in hospital settings. Hospital pharmacies also offer extensive support services, which include educating patients and providing them with an avenue for reimbursement from their respective insurance companies, thus dominating the market.
The online pharmacies segment is expected to grow at the fastest rate during the forecast years, primarily due to increasing demand for convenience and accessibility in medication procurement. Online platforms provide a cost-effective alternative to traditional brick-and-mortar pharmacies, especially for patients requiring long-term medications like DMARDs or biologics. Growth is further fueled by advancements in digital health infrastructure, improved e-commerce penetration, and the rising adoption of telemedicine services. This shift to online healthcare services was also hastened by the COVID-19 pandemic, and regulatory approvals for e-prescriptions in many regions have also provided a good environment for online pharmacies to expand.
Key regional analysis
North America dominated the psoriatic arthritis treatment market with a 39.46% market share in 2023 due to its superior healthcare infrastructure, higher awareness levels, and availability of novel therapies. The region enjoys a substantial burden of psoriatic arthritis, with more than 2 million affected people in the U.S. alone, thereby fueling the demand for appropriate treatment modalities. For instance, the presence of key market players- Amgen, Johnson & Johnson, and AbbVie has promoted a good pipeline of biologics and DMARDs in the region. Favorable reimbursement policies and high healthcare spending further support the adoption of expensive biologics and combination therapies, which supports North America's leading position in the market.
Asia Pacific is expected to grow the fastest with 11.18% CAGR during the forecast period due to several factors, including an increasing prevalence of psoriatic arthritis and rising healthcare investments. Awareness about early diagnosis and treatment, along with improving access to healthcare in countries like India, China, and other Southeast Asian countries, increases the demand for psoriatic arthritis therapies. Other than that, in the cost-sensitive markets, the adoption of biosimilars has helped in cutting the cost for greater patient access to biologics and DMARDs. Another factor in this region is that the government is undertaking initiatives that would expand coverage to healthcare while there is increased investment in telemedicine and online pharmacy services.
Need Any Customization Research On Psoriatic Arthritis Treatment Market - Inquiry Now
Some of the major key players in the Psoriatic Arthritis Treatment Market
AbbVie (Humira, Rinvoq)
Amgen (Enbrel, Aimovig)
Johnson & Johnson (Stelara, Tremfya)
Novartis (Cosentyx, Kisqali)
Merck & Co. (Remicade, Jemperli)
Pfizer (Xeljanz, Enbrel)
Bristol-Myers Squibb (Orencia, Otezla)
Eli Lilly and Company (Taltz, Olumiant)
Sanofi (Kevzara, Dupixent)
Gilead Sciences (Biktarvy, Veklury)
UCB Pharma (Cimzia, Kusabri)
Abbott Laboratories (Humira, Simulect)
Horizon Therapeutics (Tepezza, Krystexxa)
Boehringer Ingelheim (Olumiant, Actemra)
Roche (Actemra, Venclexta)
Celltrion Healthcare (Remsima, Truxima)
Mylan (Renflexis, Biosimilars in Development)
Teva Pharmaceutical Industries (Copaxone, Ajovy)
Samsung Biologics (Renflexis, Biosimilars Pipeline)
AstraZeneca (Fasenra, Imfinzi)
Suppliers (These suppliers provide key components, biosimilars, or support for biologic and pharmaceutical treatments in the market for psoriatic arthritis.)
Baxter International
Medtronic
Fresenius Kabi
Sandoz (a Novartis division)
Mylan (now part of Viatris)
Cipla
Amgen
Pfizer
Bristol-Myers Squibb
Samsung Biologics
Recent development
March 2024: Amgen announced the results from the global Phase 4 FOREMOST study, evaluating Otezla (apremilast) in patients with early oligoarticular psoriatic arthritis. This is the first placebo-controlled study specifically designed to assess individuals with oligoarticular psoriatic arthritis and early disease duration of five or fewer years.
November 7, 2024: Johnson & Johnson revealed that 43 presentations showcasing the company’s rheumatology pipeline and portfolio would be featured at the American College of Rheumatology (ACR) 2024 Annual Meeting. The presentations will include three oral sessions and a plenary session, highlighting new data on the investigational drug nipocalimab for Sjögren’s disease and new research on the impact of TREMFYA in psoriatic arthritis (PsA).
October 6, 2023: Novartis, a global leader in immuno-dermatology and rheumatology, announced that the US Food and Drug Administration (FDA) had approved an intravenous (IV) formulation of Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS), and non-radiographic axial spondyloarthritis (nr-axSpA).
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 11.08 Billion |
| Market Size by 2032 | US$ 25.41 Billion |
| CAGR | CAGR of 9.70% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug Class (NSAIDs, DMARDs, Biologics, Others) • By Route of Administration (Topical, Oral, Injectable) • By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | AbbVie, Amgen, Johnson & Johnson, Novartis, Merck & Co., Pfizer, Bristol-Myers Squibb, Eli Lilly and Company, Sanofi, Gilead Sciences, UCB Pharma, Abbott Laboratories, Horizon Therapeutics, Boehringer Ingelheim, Roche, Celltrion Healthcare, Mylan, Teva Pharmaceutical Industries, Samsung Biologics, AstraZeneca, and other players. |
Ans: The Psoriatic Arthritis Treatment Market is expected to grow at a CAGR of 9.70% during 2024-2032.
Ans: The Psoriatic Arthritis Treatment Market was USD 11.08 billion in 2023 and is expected to Reach USD 25.41 billion by 2032.
Ans: The rising awareness about PsA and its impact on patient's quality of life is leading to better early diagnosis and more timely treatments.
Ans: The “Biologics” segment dominated the Psoriatic Arthritis Treatment Market.
Ans: North America dominated the Psoriatic Arthritis Treatment Market in 2023.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends (2023) by Region
5.3 Healthcare Spending (by Region) (2023)
5.4 Trends in Drug Development and Approvals
5.5 Patient Demographics and Treatment Adherence
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Psoriatic Arthritis Treatment Market Segmentation, by Drug Class
7.1 Chapter Overview
7.2 NSAIDs
7.2.1 NSAIDs Market Trends Analysis (2020-2032)
7.2.2 NSAIDs Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 DMARDs
7.3.1 DMARDs Market Trends Analysis (2020-2032)
7.3.2 DMARDs Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Biologics
7.4.1 Biologics Market Trends Analysis (2020-2032)
7.4.2 Biologics Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Others
7.5.1 Others Market Trends Analysis (2020-2032)
7.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Psoriatic Arthritis Treatment Market Segmentation, by Route of Administration
8.1 Chapter Overview
8.2 Topical
8.2.1 Topical Market Trends Analysis (2020-2032)
8.2.2 Topical Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Oral
8.3.1 Oral Market Trends Analysis (2020-2032)
8.3.2 Oral Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Injectable
8.4.1 Injectable Market Trends Analysis (2020-2032)
8.4.2 Injectable Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Psoriatic Arthritis Treatment Market Segmentation, by Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacies
9.2.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
9.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Online Pharmacies
9.3.1 Online Pharmacies Market Trends Analysis (2020-2032)
9.3.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Retail Pharmacies
9.4.1 Retail Pharmacies Market Trends Analysis (2020-2032)
9.4.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.4 North America Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.5 North America Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.6.2 USA Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.6.3 USA Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.7.2 Canada Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.7.3 Canada Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.8.2 Mexico Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.2.8.3 Mexico Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.6.2 Poland Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.6.3 Poland Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.7.2 Romania Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.7.3 Romania Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.4 Western Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.5 Western Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.6.2 Germany Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.6.3 Germany Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.7.2 France Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.7.3 France Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.8.2 UK Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.8.3 UK Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.9.2 Italy Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.9.3 Italy Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.10.2 Spain Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.10.3 Spain Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.13.2 Austria Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.13.3 Austria Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.4 Asia Pacific Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.5 Asia Pacific Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.6.2 China Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.6.3 China Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.7.2 India Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.7.3 India Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.8.2 Japan Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.8.3 Japan Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.9.2 South Korea Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.9.3 South Korea Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.10.2 Vietnam Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.10.3 Vietnam Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.11.2 Singapore Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.11.3 Singapore Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.12.2 Australia Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.12.3 Australia Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.4 Middle East Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.5 Middle East Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.6.2 UAE Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.6.3 UAE Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.4 Africa Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.5 Africa Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.4 Latin America Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.5 Latin America Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.6.2 Brazil Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.6.3 Brazil Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.7.2 Argentina Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.7.3 Argentina Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.8.2 Colombia Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.8.3 Colombia Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Route of Administration (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Psoriatic Arthritis Treatment Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
11. Company Profiles
11.1 AbbVie
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Amgen
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Johnson & Johnson
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Novartis
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Merck & Co.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Pfizer
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Bristol-Myers Squibb
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Eli Lilly and Company
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 Sanofi
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Gilead Sciences
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Drugs Class
NSAIDs
DMARDs
Biologics
Others
By Route of Administration
Topical
Oral
Injectable
By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The global 3D Printing Medical Devices Market Size was valued at USD 2.69 billion in 2023 and is expected to reach USD 11.46 billion by 2032 and grow at a CAGR of 17.49% by 2024-2032.
The Biopreservation Market size was estimated at USD 3.5 billion in 2023 and is expected to reach USD 14.3 billion by 2032 at a CAGR of 17.0% during the forecast period of 2024-2032.
The Erectile Dysfunction Treatment Devices Market is expected to grow from USD 1.58 billion in 2023 to USD 3.43 billion by 2032, at a compound annual growth rate of 9.03% during the forecast period 2024-2032.
Upstream Bioprocessing Market was valued at USD 22.79 Bn in 2023 and is anticipated to touch USD 82.10 Bn by 2032, growing at a CAGR of 15.35% from 2024-2032.
Glycomics Market was valued at USD 1.68 billion in 2023 and is expected to reach USD 5.33 billion by 2032, growing at a CAGR of 13.76% from 2024 to 2032.
The ATP Assays Market valued USD 0.93 billion in 2023 which is expected to boost USD 1.98 billion by 2032, CAGR 8.77% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
